A global resource to translational medicine: the International Park of Translational Medicine and BioMedicine (IPTBM)

Journal of Translational Medicine

Xiangdong Wang²  Michael N Liebman⁴  Francesco M Marincola³  Xiaodan Wu¹ 

[1]Department of Respiratory Medicine, Fudan University, Shanghai, China

[2]Biomedical research Center, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

[3]Section of Infectious Disease and Immunogenetics, Department of Transfusion Medicine, Clinical Center, National Institutes of Heath, Bethesda, MD, USA

[4]Strategic Medicine, Inc, Bethesda, MD, USA

关键词: Strategy;    Management;    Development;    Projects;    International;    Translational medicine;   

Others  :  828235
DOI  :  10.1186/1479-5876-11-8

 received in 2012-12-31, accepted in 2013-01-07,  发布年份 2013

【 摘 要 】

Translational science consists of research and development that integrates multiple resources to expedite the successful treatment of disease. The International Park of Translational BioMedicine (IPTBM) is currently being developed within the interface between Zhejiang Province and Shanghai Municipality. IPTBM has been designed to pioneer comprehensive biomedical research that spans the continuum from the education of young scientists to providing the infrastructure necessary for clinical testing and direct observation to better understand human biology while promoting viable commercial results within a vibrant biotechnology community. IPTBM’s goal is to attract global partners organized around five fundamental pillars: 1) Institutional Development, 2) Project Implementation, 3) Development and Production, 4) Investment and 5) Regulatory Clusters to address the needs of an international platform of scientists, institutes, universities, commercial enterprises, investors, politicians, and other stakeholders. The IPTBM differs from existing models including CTSA’s (US, NIH) technology because of its comprehensive approach to merge education, research, innovation, and development to translate clinical and public health needs into target-oriented and cost-efficient projects.

【 授权许可】

   
2013 Wu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Marincola FM: Translational medicine: a two-way road. J Transl Med 2003, 1:1. BioMed Central Full Text
• [2]Zerhouni EA: The NIH roadmap. Science 2003, 302:63-72.
• [3]Korn D: Reengineering academic medical centers: reengineering academic values? Acad Med 1996, 71(10):1033-1043.
• [4]Zerhouni EA: Translational and clinical science — time for a New vision. N Engl J Med 2005, 353:1621-1623.
• [5]Fleming M, Burnham EL, Huskins WC: Mentoring translational science investigators. JAMA 2012, 308(19):1981-1982.
• [6]Abraham E, Marincola FM, Chen ZN, Wang XD: Clinical and translational medicine: integrative and practical science. ClinTransl Med 2012, 1:1.
• [7]Wang XD: A new vision of definition, commentary, and understanding in clinical and translational medicine. ClinTransl Med 2012, 1:5.
• [8]Birkinshaw J, Hood N: Unleash innovation in foreign subsidiaries. Harv Bus Rev 2001, 79(3):131-137.
• [9]Wang XD, Marincola FM: A decade plus of translation: what do we understand? ClinTransl Med 2012, 1:3.